Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration.
暂无分享,去创建一个
G Milano | G. Milano | J. Fischel | P. Formento | J Gioanni | P Formento | J L Fischel | V Troger | J. Gioanni | V. Troger | Gérard Milano
[1] J. Whitehouse,et al. Cis-platinum: a new anticancer agent. , 1979, British medical journal.
[2] N. Vogelzang. Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Olshen,et al. Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.
[4] James B. Mitchell,et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.
[5] B. Brown,et al. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. , 1973, Cancer research.
[6] B. Barlogie,et al. Effects of cis-dichlorodiammineplatinum(II) on human colon carcinoma cells in vitro. , 1979, Cancer research.
[7] D. V. Von Hoff,et al. Cis-diamminedichloroplatinum (II). A new anticancer drug. , 1977, Annals of internal medicine.
[8] B. Hill,et al. Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitro , 1983, International journal of cancer.
[9] M. Straus,et al. Effects of pulse and continuous intravenous infusion of cis-diamminedichloroplatinum on L1210 leukemia in vivo. , 1981, Cancer research.
[10] B. Hecquet,et al. Uptake of platinum compounds in human tumors. In vitro study. , 1986, Bulletin du cancer.
[11] L. Ferrari,et al. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. , 1986, Cancer treatment reports.
[12] F. Petrucci,et al. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Eichholtz-Wirth,et al. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. , 1986, British Journal of Cancer.
[14] M. Posner,et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. , 1988, Cancer research.
[15] H. Pinedo,et al. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. , 1982, European journal of cancer & clinical oncology.
[16] C. Anderson,et al. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Einhorn,et al. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Rozencweig,et al. Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay. , 1988, European journal of cancer & clinical oncology.
[19] H. Pinedo,et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin , 1986, Clinical pharmacology and therapeutics.